AI Engines For more Details: Perplexity Kagi Labs You
Antineoplastic Activity: Floxuridine belongs to the class of medications known as antimetabolites. It works by interfering with the synthesis of DNA and RNA, which are essential for the growth and replication of cancer cells. By inhibiting nucleic acid synthesis, floxuridine prevents cancer cells from proliferating and induces their death.
Treatment of Colorectal Cancer: Floxuridine is commonly used in the treatment of colorectal cancer, particularly when the cancer has spread to the liver (metastatic colorectal cancer). It may be administered directly into the hepatic artery (intra-arterial infusion) to target tumors in the liver.
Administration Route: Floxuridine is typically administered as an intravenous infusion or through direct injection into the hepatic artery. In the case of hepatic artery infusion, floxuridine is delivered directly to the liver, allowing for higher concentrations of the drug to reach the tumor while minimizing systemic side effects.
Adverse Effects: Common side effects of floxuridine may include gastrointestinal symptoms such as nausea, vomiting, diarrhea, and mucositis (inflammation of the mucous membranes). Bone marrow suppression, resulting in decreased production of blood cells (myelosuppression), may also occur, leading to anemia, leukopenia, and thrombocytopenia.
Liver Toxicity: Floxuridine can cause hepatotoxicity (liver damage), particularly when administered via hepatic artery infusion. Hepatic artery occlusion or liver dysfunction may occur as a result of the infusion procedure, necessitating close monitoring of liver function during treatment.
Hand-Foot Syndrome: Floxuridine may cause a side effect known as hand-foot syndrome (palmar-plantar erythrodysesthesia), characterized by redness, swelling, and pain in the palms of the hands and soles of the feet. This condition can be dose-limiting and may require dose adjustments or discontinuation of treatment.
Bone Marrow Suppression: Floxuridine can suppress bone marrow function, leading to a decreased production of white blood cells, red blood cells, and platelets. This can increase the risk of infections, anemia, and bleeding, necessitating regular monitoring of blood cell counts during treatment.
Contraindications and Precautions: Floxuridine is contraindicated in individuals with known hypersensitivity to the drug or its components. It should be used with caution in patients with preexisting liver disease or impaired bone marrow function. Pregnancy and breastfeeding are generally contraindicated due to the potential risk of harm to the fetus or infant.
Monitoring and Supportive Care: Patients receiving floxuridine therapy require close monitoring of liver function, blood cell counts, and renal function. Supportive care measures, such as antiemetic medications to manage nausea and vomiting, may be prescribed to improve tolerance to treatment.
Combination Therapy: Floxuridine may be used in combination with other chemotherapy drugs or radiation therapy as part of a multidisciplinary approach to cancer treatment. The choice of treatment regimen depends on factors such as the type and stage of cancer, as well as the patient's overall health and treatment goals.
Rank | Probiotic | Impact |
---|---|---|
species | Bacteroides uniformis | Reduces |
species | Escherichia coli | Reduces |
species | Lacticaseibacillus paracasei | Reduces |
species | Parabacteroides distasonis | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
---|---|---|---|
ADHD | 3.4 | 0.5 | 5.8 |
Age-Related Macular Degeneration and Glaucoma | 0.5 | 0.3 | 0.67 |
Allergic Rhinitis (Hay Fever) | 2.8 | 2.8 | |
Allergies | 2.5 | 1.5 | 0.67 |
Allergy to milk products | 2 | 0.8 | 1.5 |
Alopecia (Hair Loss) | 1 | 1 | |
Alzheimer's disease | 2.3 | 3.8 | -0.65 |
Amyotrophic lateral sclerosis (ALS) Motor Neuron | 2 | 1 | 1 |
Ankylosing spondylitis | 4 | 1.5 | 1.67 |
Anorexia Nervosa | 0.3 | 1.6 | -4.33 |
Antiphospholipid syndrome (APS) | 2.5 | 2.5 | |
Asthma | 1.5 | 1 | 0.5 |
Atherosclerosis | 0 | 2 | 0 |
Atrial fibrillation | 1.4 | 2.3 | -0.64 |
Autism | 9.3 | 6 | 0.55 |
Barrett esophagus cancer | 0.5 | -0.5 | |
benign prostatic hyperplasia | 0.5 | 0.5 | |
Biofilm | 3 | 3 | |
Bipolar Disorder | 1.3 | 1 | 0.3 |
Brain Trauma | 1 | -1 | |
Cancer (General) | 0.5 | 3 | -5 |
Carcinoma | 2.8 | 1.3 | 1.15 |
Celiac Disease | 3.5 | 1.3 | 1.69 |
Cerebral Palsy | 1 | 1 | 0 |
Chronic Fatigue Syndrome | 8.5 | 4.5 | 0.89 |
Chronic Kidney Disease | 2.8 | 0.7 | 3 |
Chronic Lyme | 1 | -1 | |
Chronic Obstructive Pulmonary Disease (COPD) | 2.5 | 0.5 | 4 |
Chronic Urticaria (Hives) | 2.5 | 2 | 0.25 |
Coagulation / Micro clot triggering bacteria | 2.3 | 1 | 1.3 |
Colorectal Cancer | 5.3 | 0.1 | 52 |
Constipation | 2 | 0.5 | 3 |
Coronary artery disease | 1.1 | 0 | 0 |
COVID-19 | 9.6 | 11.3 | -0.18 |
Crohn's Disease | 7.3 | 3 | 1.43 |
cystic fibrosis | 1.5 | 1 | 0.5 |
deep vein thrombosis | 1.5 | 1 | 0.5 |
Depression | 11.8 | 4.3 | 1.74 |
Dermatomyositis | 0.5 | 0.5 | |
Eczema | 1.5 | 3 | -1 |
Endometriosis | 2.8 | 0.5 | 4.6 |
Epilepsy | 2.5 | 1.1 | 1.27 |
Fibromyalgia | 2.6 | 3 | -0.15 |
Functional constipation / chronic idiopathic constipation | 5.8 | 4.5 | 0.29 |
gallstone disease (gsd) | 1.3 | 0.5 | 1.6 |
Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 2 | 0.5 | 3 |
Generalized anxiety disorder | 2.5 | 1 | 1.5 |
giant cell arteritis | 0.5 | -0.5 | |
Glioblastoma | 0.5 | -0.5 | |
Gout | 0 | 0 | |
Graves' disease | 0.8 | 0.5 | 0.6 |
Halitosis | 0.5 | 0.5 | 0 |
Hashimoto's thyroiditis | 1 | 0.5 | 1 |
Hidradenitis Suppurativa | 0.5 | 0.5 | |
High Histamine/low DAO | 3 | 0 | 0 |
hypercholesterolemia (High Cholesterol) | 1 | 1 | |
hyperglycemia | 0.5 | 0.8 | -0.6 |
hypertension (High Blood Pressure | 1.8 | 5 | -1.78 |
Hypothyroidism | 0.5 | -0.5 | |
Hypoxia | 0.8 | 0.8 | |
IgA nephropathy (IgAN) | 5.5 | -5.5 | |
Inflammatory Bowel Disease | 7 | 4.8 | 0.46 |
Insomnia | 1 | 1 | 0 |
Intelligence | 1.5 | 1 | 0.5 |
Intracranial aneurysms | 0.8 | 0.8 | |
Irritable Bowel Syndrome | 5 | 4.3 | 0.16 |
Liver Cirrhosis | 3.3 | 2 | 0.65 |
Long COVID | 8.9 | 3 | 1.97 |
Low bone mineral density | 0.5 | -0.5 | |
Lung Cancer | 1.5 | 0 | 0 |
Mast Cell Issues / mastitis | 1 | 0 | 0 |
ME/CFS with IBS | 2 | 0.5 | 3 |
ME/CFS without IBS | 3.5 | 1.5 | 1.33 |
Menopause | 1 | 1 | |
Metabolic Syndrome | 7.8 | 6.8 | 0.15 |
Mood Disorders | 12.8 | 4.8 | 1.67 |
multiple chemical sensitivity [MCS] | 1.5 | 1.5 | |
Multiple Sclerosis | 4.3 | 6.5 | -0.51 |
Multiple system atrophy (MSA) | 2 | 0 | 0 |
neuropathic pain | 1.5 | -1.5 | |
Neuropathy (all types) | 0.5 | 0.5 | 0 |
neuropsychiatric disorders (PANDAS, PANS) | 1.5 | 1.5 | |
Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 2.5 | 1.2 | 1.08 |
NonCeliac Gluten Sensitivity | 0.5 | 0.5 | 0 |
Obesity | 6.8 | 3.3 | 1.06 |
obsessive-compulsive disorder | 6.8 | 3.1 | 1.19 |
Osteoarthritis | 4 | 0 | 0 |
Osteoporosis | 2 | 0.5 | 3 |
pancreatic cancer | 1 | 1 | |
Parkinson's Disease | 5.8 | 5.4 | 0.07 |
Polycystic ovary syndrome | 2.8 | 1.5 | 0.87 |
Postural orthostatic tachycardia syndrome | 0.5 | 0 | 0 |
Premenstrual dysphoric disorder | 0.3 | -0.3 | |
primary biliary cholangitis | 1 | -1 | |
Psoriasis | 3 | 3.3 | -0.1 |
rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 4.8 | 3 | 0.6 |
Rosacea | 0 | 1 | 0 |
Schizophrenia | 4.3 | 1 | 3.3 |
scoliosis | 0 | 0 | 0 |
Sjögren syndrome | 2.8 | 1.9 | 0.47 |
Sleep Apnea | 0 | 1.5 | 0 |
Slow gastric motility / Gastroparesis | 1.5 | 1.5 | |
Small Intestinal Bacterial Overgrowth (SIBO) | 1.5 | 1.5 | |
Stress / posttraumatic stress disorder | 2.8 | 2 | 0.4 |
Systemic Lupus Erythematosus | 4.8 | 1 | 3.8 |
Tic Disorder | 1.5 | 1 | 0.5 |
Tourette syndrome | 0.5 | -0.5 | |
Type 1 Diabetes | 4 | 2.5 | 0.6 |
Type 2 Diabetes | 8.3 | 7.3 | 0.14 |
Ulcerative colitis | 3.5 | 6.3 | -0.8 |
Unhealthy Ageing | 5.5 | 1.2 | 3.58 |
Vitiligo | 1.5 | 0.8 | 0.88 |
This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.
Explanations /Info /Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations.Please report any to us for correction.
Copyright 2016 - 2024 Lassesen Consulting, LLC[2007], DBA, Microbiome Prescription
All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users.U.S.Code Title 18 PART I CHAPTER 47 Β§β―1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license.There is no charge for individual personal use.Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling(and thus infererence ) based on studies.The data sources are usually given for those that wish to consider alternative inferences.theories and models.
Inventions /Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions,
or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not in strict compliance with Personal Health Information Laws. [34.204.176 ]
Due to AI drones slamming this site, we have added IP blocking on excessive calls. Email us if you get blocked and send this [34.204.176 ]